



***NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES***

## **BioNxt Solutions Inc. Provides Update on Prior Debenture**

**Vancouver, British Columbia, Canada (January 8, 2025)** - BioNxt Solutions Inc. (“**BioNxt**” or the “**Company**”) (CSE: BNXT / OTC: XPHYF / FSE: 4XT) announces that prior to expiry, it amended the terms of a previously issued unsecured convertible debenture in the principal amount of \$2,808,000, bearing interest at a rate of 8% per annum and previously maturing on December 7, 2024 (the “**Debenture**”). The maturity date of the Debenture was extended one year to December 7, 2025, and the Company is now entitled, from time to time, to issue common shares in the capital of the Company (“**Interest Shares**”) at a price of \$0.285 per Interest Share, being the market price at the time of amendment, in satisfaction of accrued and unpaid interest. For further details regarding the Debenture, see the Company’s news release dated December 7, 2022, a copy of which is available under the Company’s profile at [www.sedarplus.ca](http://www.sedarplus.ca).

Pursuant to the terms of the amended Debenture, the Company issued 1,459,649 Interest Shares in satisfaction of \$416,000 in accrued and unpaid interest. Such Interest Shares are subject to a hold period expiring May 9, 2025.

### **About BioNxt Solutions Inc.**

BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

For more Company information, please visit <https://bionxt.com/> or review its profiles on [www.sedarplus.ca](http://www.sedarplus.ca) and on the Canadian Securities Exchange’s website, [www.thecse.com](http://www.thecse.com).

### **BioNxt Solutions Inc.**

Hugh Rogers, CEO and Director  
Email: [info@bionxt.com](mailto:info@bionxt.com)  
Phone: +1 780-818-6422

The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities



laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

### **Forward-Looking Information**

*The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.*

*This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.*